‘HER2 positive’ non-metastatic breast cancer patients are eligible for anti HER2 drugs hence, on the basis of the partial response of ‘HER2 negative’ metastatic breast cancer to bevacizumab, its use was studied in the latter category of patients. This evidence concerns the gene ERBB2 and breast cancer.